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Abstract Purpose: To study the
effects of pretreatment with levosim-
endan (LEVO, a Ca2?-sensitizer and
KATP
? channel opener) and/or the
KATP
? channel antagonist glibencla-
mide (GLIB) on systemic
hemodynamics, metabolism, and
regional gastromucosal oxygenation
during hypoxic hypoxemia. Meth-
ods: Chronically instrumented,
healthy dogs (24–32 kg, n = 6 per
group, randomized cross-over design)
were repeatedly sedated, mechani-
cally ventilated (FiO2 *0.3) and
subjected to the following interven-
tions: no pretreatment, LEVO
pretreatment, GLIB pretreatment, or
combined LEVO ? GLIB pretreat-
ment, each followed by hypoxic
hypoxemia (FiO2 *0.1). We mea-
sured cardiac output (CO, ultrasonic
flow probes), oxygen consumption
(VO2, indirect calorimetry), and gas-
tromucosal microvascular
hemoglobin oxygenation (lHbO2,
spectrophotometry). Statistics: data
are presented as mean ± SEM and
compared by one-way ANOVA
(direct drug effects within group) and
two-way ANOVA (between all hyp-
oxic conditions) both with Bonferroni
corrections; p \ 0.05. Results: In
LEVO-pretreated hypoxemia, CO
was significantly higher compared to
unpretreated hypoxemia. The
increased CO was neither associated
with an increased VO2 nor with
markers of aggravated anaerobiosis
(pH, BE, lactate). In addition, LEVO
pretreatment did not further compro-
mise gastromucosal lHbO2 in
hypoxemia. After combined
LEVO ? GLIB pretreatment, sys-
temic effects of GLIB were apparent,
however, CO was significantly higher
than during unpretreated and GLIB-
pretreated hypoxemia, but equal to
LEVO-pretreated hypoxemia, indi-
cating that GLIB did not prevent the
increased CO in LEVO-pretreated
hypoxia. Conclusions: LEVO pre-
treatment resulted in improved
systemic circulation (CO) during
hypoxemia without fueling systemic
VO2, without aggravating systemic
anaerobiosis markers, and without
further compromising microvascular
gastromucosal oxygenation. Thus,
LEVO pretreatment may be an option
to support the systemic circulation
during hypoxia.
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Introduction
Hypoxemia complicates critical care settings, ranging
from progressed lung disease to certain medical inter-
ventions [1–3]. Clearly, reversing hypoxemia is pivotal
[4], but adapting pharmacological interventions to support
the subject during impending or actual hypoxemia also
appears beneficial. Systemic hypoxemia triggers multiple
patho-mechanisms [5] also affecting the cardiovascular
system: among others, at the cardiac level hypoxia
depresses cardiac function by myofilament Ca2?-desen-
sitization [6, 7], and at the vascular level hypoxia triggers
activation of KATP
? channels [8], facilitating blood flow to
tissues otherwise at risk for hypoperfusion by intense
vasoconstriction.
In this context, the inodilator levosimendan (LEVO)
appears to be an attractive option to support the cardio-
vascular system at risk in (impending) hypoxemia since it
acts both as cardiac myofilament Ca2?-sensitizer and
KATP
? channel opener, thus reversing hypoxia-induced
cardiodepression and supporting regional vasodilation.
This appears to be particularly of interest in hypoxic
settings, since LEVO putatively increases cardiac output
(CO) partly independent of an additional increase in
oxygen consumption (VO2) [9].
Hypoxia, like other cardiovascular stressors, triggers
impairment of splanchnic oxygenation, likely through a
combination of abnormal mesenteric perfusion [10–12]
and hypoxemia. However, particularly the gastrointestinal
mucosa is susceptible to hypoxia, and mucosal hypoxia
appears to trigger the development of critical illness [13].
Thus, interventions intended to improve systemic
(hemodynamic) variables during hypoxia should not fur-
ther compromise regional mucosal circulation or
oxygenation [14]. Therefore, in addition to systemic
variables, we measured the effects on regional gastro-
mucosal oxygenation.
Clinically, LEVO is primarily indicated for the treat-
ment of acute and chronic ischemic cardiac failure, with
promising clinical data available [15, 16]. Moreover,
LEVO is also increasingly advocated to treat nonischemic
cardiac failure, including septic or toxic cardiodepression
[17–23]. The beneficial effects of LEVO, in addition to
positive inotropic effects, may be caused by vasodilation
[24]. Mechanistically, vasodilation by LEVO is mediated
by activation of KATP
? channels, which also appear
involved in the vasodilation triggered by hypoxia [8, 25].
These KATP
? channels, activated by LEVO or hypoxia,
are pharmacologically blocked by glibenclamide (GLIB)
[26–30]. In this context, GLIB pretreatment has previ-
ously been published as a research tool to study the
contribution of GLIB-sensitive KATP
? channels to the
effects of LEVO and other cardiovascular challenges [26–
30]. Thus, to elucidate the contribution of KATP
? channels
in the present study, we tested if KATP
? channel blockade
by GLIB pretreatment would alter the (circulatory) con-
dition during hypoxia, both with and without a LEVO
pretreatment.
GLIB, based on the same mechanism, i.e., antago-
nizing KATP
? channel-dependent vasodilation, is of
growing interest in intensive care medicine [31]. In this
context, GLIB is studied as nonadrenergic vasopressor
in various shock-related vasodilatory states, caused by
excessive KATP
? channel activation. Examples for this
therapeutic concept are septic or hemorrhagic vasodi-
lation [32, 33]. In this regard, GLIB increases systemic
vascular resistance and thus arterial blood pressure
[32].
In the present study, the combination of LEVO (to
increase cardiac contractility) and GLIB (to increase
systemic vascular resistance) could achieve the putatively
beneficial combination of antagonizing both possible
cardiodepressant and vasodilatory effects of systemic
hypoxia.
Materials and methods
The data derive from repetitive experiments on healthy
dogs (foxhounds, n = 6, 24–32 kg) treated in accordance
with the National Institutes of Health guidelines for ani-
mal care and with approval of the District Governmental
Animal Investigation Committee.
For the continuous measurement of cardiac output
(CO), ultrasonic flow transducers (S-series, Transonic,
Ithaca, NY, USA) were chronically implanted around the
pulmonary artery [34]. Before the experiments, food was
withheld for 12 h. The experiments were performed under
sedation with sevoflurane (end-tidal concentration 3.0
vol%, corresponding to *1.25 MAC in dogs [35]) and
neuromuscular block (rocuronium 0.6 mg kg-1, followed
by 1.0 mg kg-1 h-1). Mechanical ventilation (FiO2 0.3;
tidal volume 12.5 mL kg-1 in dogs [36], respiratory rate
*20 min-1) was adjusted to maintain normocapnia as
verified by continuous capnography (end-tidal CO2
35 torr) and arterial blood gas analysis. The dogs were
covered with warming blankets to maintain body tem-
perature (*37.5C, rectal thermoprobe).
Measurements
Systemic oxygen consumption
Systemic oxygen consumption (VO2) was measured
continuously by indirect calorimetry (Deltatrac-II meta-
bolic monitor, Datex, Helsinki, Finland) and thus was
methodologically independent from the determination of
CO and DO2 [9].
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Systemic hemodynamics and oxygenation
We continuously measured heart rate (HR, electrocar-
diogram), mean arterial (aortic) pressure (MAP; P23ID,
Elk Grove, CA, USA), central venous pressure (P23ID;
right atrial catheter tip position confirmed by fluoros-
copy), and ultrasound-derived CO (flowmeter T106,
Transonic). At the end of each intervention, we performed
transpulmonary thermodilution (PiCCO monitor with
thermistor-tipped carotid catheter PV-2014L, Pulsion,
Munich, Germany; measurements performed according to
the manufacturer; with *0.4 mL kg-1 iced saline) to
determine the following: global end diastolic volume
(GEDV), derived intrathoracic blood volume (ITBV), and
extravascular lung water (EVLW). The PiCCO system
also provided the pulse-contour-derived stroke volume
variation (SVV) and the estimate of cardiac contractility
?dP/dtmax. This system is validated to measure EVLW in
dogs [37] and has also been applied in other canine
studies [38].
Intermittently we measured arterial blood gas tensions
(PaO2, PaCO2) and acid/base-related variables [pH, base
excess (BE); ABL-700, Radiometer, Copenhagen, Den-
mark; no buffer solutions were used]. Additionally, we
determined arterial serum metabolites (glucose, lactate)
and electrolytes ([K?], [Ca2?], [Na?], [Cl-]). According
to standard formulas, we calculated systemic vascular
resistance (SVR), arterial oxygen content (CaO2), and
systemic oxygen transport (DO2).
Gastromucosal oxygenation
Gastromucosal oxygenation was continuously assessed by
reflectance spectrophotometry [9, 39]. Briefly, light
(502–628 nm) is transmitted to the tissue via a micro light
guide, and the reflected light is analyzed for the per-
centage of oxygenated microvascular hemoglobin
(lHbO2). The flexible probe (diameter 2.0 mm) was
introduced into the stomach via an orogastric silicone
tube (14 Charrie`re). During the experiments, correct
probe position was confirmed by online evaluation of the
signal quality (software version 2.0).
Experimental program
After induction (propofol 4 mg kg-1 i.v.) and endotra-
cheal intubation, all catheters were inserted and 30 min
was allowed to establish steady-state conditions. Blood
was sampled for baseline analysis, and thereafter a ran-
domization was performed to allocate the dogs to the
experimental groups.
Hypoxia episodes
The hypoxic episodes were induced by switching FiO2
from 0.30 to 0.11 [40], as continuously measured (Cap-
nomac ultima, Datex Instrumentarium, Helsinki, Finland).
Each hypoxic episode was maintained for 15 min to allow
steady states of the measured variables to be achieved.
Drugs
The agents LEVO and GLIB were infused as follows by a
pressure-limited infusion pump via the central venous
catheter.
LEVO
After baseline measurements, LEVO (Simdax, Abbott,
Wiesbaden, Germany) was administered with an initial
loading dose of 20.0 lg kg-1 over 15 min, followed by
continuous infusion of 0.25 lg kg-1 min-1 for the
remaining experimental period, a dosing regimen adapted
from a similar canine model [9].
GLIB
GLIB (G0639, Sigma, Frankfurt, Germany), as
KATP
? channel antagonist, was infused at a dose of
0.2 mg kg-1 over 10 min, and 30 min were allowed for
stabilization. This dose was derived from previous canine
studies addressing the contribution of KATP
? channels to
the effects of LEVO and other cardiovascular modulators
[26–30].
Experimental protocols
Group I
This protocol served to study the effects of hypoxia per se
and to study the associated effects of GLIB pretreatment.
After steady-state baseline measurements, a first hypoxic
challenge was performed. After 60 min recovery from
this hypoxia (measurements after 30 and 60 min recov-
ery), GLIB was infused. Following this GLIB
pretreatment, a second hypoxic episode was induced.
Group II
This protocol served to study the effects of LEVO pre-
treatment on hypoxia and further to study the role of
GLIB pretreatment in this regard. After a baseline period,
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LEVO pretreatment was administered, and thereafter a
first hypoxic episode was induced. After 60 min recovery
from this hypoxia (measurements after 30 and 60 min
recovery), with LEVO continuously infused, GLIB pre-
treatment was administered. Thereafter, with the
combined LEVO ? GLIB pretreatment, a second hyp-
oxic challenge was induced.
Statistical analysis
Statistical analysis was performed using Prism software
(version 5.0, GraphPad, La Jolla, CA, USA). Data are
presented as absolute values of mean ± SEM for n = 6
animals per group in the manuscript and tables. Direct
drug effects (before onset of hypoxemia) were described
by one-way ANOVA for repeated measurements, cor-
rected for multiple comparisons (Bonferroni). Differences
during hypoxemia were tested both between groups (i.e., I
and II) and between the hypoxia conditions (i.e., without
and with GLIB pretreatment) using a two-way ANOVA,
corrected for multiple comparisons (Bonferroni). Signifi-
cance was assumed at p \ 0.05.
Results
Hypoxia model
Hypoxia was induced by reducing FiO2 from 0.3 to 0.11,
with maintenance of end-tidal CO2 (35 torr) and end-tidal
sevoflurane (3.0 vol%) concentrations. This was achieved
for all four hypoxic conditions without significant inter-
or intragroup differences (Table 1).
Hypoxia in unpretreated animals
In our hypoxia model, reduction of FiO2 from 0.3 to 0.11
in unpretreated animals decreased PaO2 from 133 ± 9 to
39 ± 1 Torr and thereby SaO2 from 98 ± 0 to 68 ± 1%.
Together with an unchanged Hb (stable at *12.5 g dL-1,
data not shown) this decreased CaO2 from 17.3 ± 0.8 to
11.7 ± 0.6 mL dL-1 (Table 1). At the regional level,
gastromucosal lHbO2 decreased from 56 ± 3 to
32 ± 4% (Fig. 1). DO2 decreased from 14 ± 1 to
9 ± 1 mL kg-1 min-1, since CaO2 decreased without
compensatory increase in CO. However, systemic VO2
was preserved at *3.5 mL kg-1 min-1 (Table 2).
Mechanical ventilation adjusted to maintain etCO2 at
35 Torr maintained PaCO2 at 35–38 Torr. Acid/base-
related variables remained stable, i.e., pH at 7.35–7.37
and HCO3
- at *20 mmol L-1. Glucose and lactate
(Table 1) and all measured electrolytes remained close to
baseline (data not shown).
Hypoxia in GLIB-pretreated animals
GLIB pretreatment, used to block GLIB-sensitive
KATP
? channels, significantly increased SVR and signifi-
cantly affected some blood-derived variables, e.g., it
decreased arterial glucose concentration (Tables 1, 2).
Hypoxia after GLIB pretreatment resulted in a similar
decreased CaO2 (11.1 ± 0.5 mL dL
-1), compared to
unpretreated animals (11.7 ± 0.6 mL dL-1). Also, no
statistical differences were observed in ventilation- and
acid/base-derived parameters (PaCO2, pH, and BE) and
the O2-related variables lHbO2, DO2, and VO2 between
these two hypoxic conditions. However, in GLIB-pre-
treated hypoxia, arterial lactate was significantly lower
(*1.2 mmol L-1) compared to unpretreated hypoxia
(*2.6 mmol L-1). Systemic hemodynamics (i.e., MAP
and CO) did not differ between these two hypoxic epi-
sodes. Arterial electrolytes did not differ, and arterial
glucose was significantly lower in GLIB-pretreated
hypoxia (*80 mg dL-1) compared to unpretreated
hypoxia (*110 mg dL-1) (Table 1).
Hypoxia in LEVO-pretreated animals
LEVO pretreatment at the macrocirculatory level signif-
icantly increased SV, CO, ?dP/dtmax, and DO2 and
decreased SVR, without significant changes in HR. At the
microcirculatory level, LEVO pretreatment significantly
increased lHbO2 at a stable systemic SaO2.
Hypoxia after LEVO pretreatment resulted in a similar
decrease in CaO2 to 10.3 ± 0.5 mL dL
-1, compared to
unpretreated animals. In LEVO-pretreated hypoxia, CO
was significantly higher compared to unpretreated hypoxia,
i.e., *100 versus *80 mL kg-1 min-1 (Figs. 2, 3). This
was not paralleled by systemic VO2, which was comparable
to unpretreated animals at *3.5 mL kg-1 min-1. Also
gastromucosal lHbO2 equally decreased in both unpre-
treated and LEVO-pretreated animals to *30% (Fig. 1).
Systemic vascular resistance was significantly lower in
LEVO-pretreated hypoxia, compared to unpretreated
hypoxia.
Hypoxia in LEVO- plus GLIB-pretreated animals
Administration of GLIB during LEVO infusion induced
significant effects, e.g., GLIB significantly decreased serum
glucose from 103 ± 4 to 87 ± 3 mg dL-1 (Table 1).
Hypoxic ventilation under combined pretreatment
with LEVO and GLIB resulted in a PaO2 of 32 Torr.
During hypoxia with LEVO ? GLIB pretreatment, CaO2
tended to be lower compared to unpretreated hypoxia
(9.4 ± 0.9 vs. 11.7 ± 0.6 mL dL-1), however, without
statistical significance. CO was significantly higher than
during hypoxia in solely GLIB-pretreated animals and did
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not differ from solely LEVO-pretreated animals (Fig. 2).
SVR was significantly lower in LEVO ? GLIB-pre-
treated hypoxia compared to GLIB-pretreated hypoxia.
Systemic VO2 was comparable to all other hypoxic con-
ditions at *3.5 mL kg-1 min-1. Glucose, as expected,
significantly decreased with GLIB.
Thermodilution-derived variables
Transpulmonary thermodilution (PiCCO) revealed no
significant differences in the estimated blood volumes
ITBV (*20 mL kg-1) and GEDV (*16 mL kg-1) or
estimated EWLV (*9 mL kg-1) between the four hyp-
oxemia conditions (data not shown).
Discussion
For the present study we developed a model of moderate
hypoxic hypoxemia, adapting reported canine hypoxia
models [40, 41]. Repetitive experiments were performed
Fig. 1 Gastric mucosal microcirculatory hemoglobin oxygenation
(lHbO2). Gastromucosal lHbO2 during normoxia (FiO2 *0.3, thin
outlined bars) and the two hypoxia episodes (FiO2 * 0.1, bold
outlined bars) of the two experimental groups I (left bar per
condition) and II (right bar per condition). Levosimendan was not
given in group I, thus condition LEVO in group I is not determined
(n.d.). Filling patterns: gray no pretreatment, downward stripes
levosimendan (LEVO) pretreatment, upward stripes glibenclamide
(GLIB) pretreatment, hatches levosimendan ? glibenclamide pre-
treatment. Recovery-30 and recovery-60 are measurement points at
30 and 60 min of normoxic recovery. Mean ± SEM for n = 6 per
group. aNo difference between hypoxia episodes, bsignificant
difference within one group’s hypoxia episodes, csignificant
difference between the two groups’ hypoxia episodes, * significant
drug effects of LEVO and $ GLIB
Table 2 Systemic hemodynamic variables and systemic oxygen metabolism
Variable Condition Baseline LEVO Hypoxia-1 Recovery-30 Recovery-60 GLIB Hypoxia-2 Recovery-30
SV (mL) Group I 18 ± 1 (n.d.) 17 ± 1b 18 ± 1 18 ± 1 17 ± 1 15 ± 1b 17 ± 1
Group II 20 ± 1 22 ± 1* 21 ± 1b 22 ± 1 22 ± 1 21 ± 1 21 ± 1b 20 ± 1
HR (bpm) Group I 116 ± 3 (n.d.) 121 ± 2a 114 ± 3 113 ± 3 112 ± 2 117 ± 2a 112 ± 2
Group II 111 ± 6 117 ± 6 126 ± 4a 116 ± 5 117 ± 5 116 ± 4 124 ± 4a 119 ± 4
MAP (mmHg) Group I 62 ± 3 (n.d.) 66 ± 4a 63 ± 2 62 ± 2 65 ± 2 62 ± 4a 63 ± 1
Group II 61 ± 1 62 ± 1 67 ± 4a 64 ± 2 62 ± 1 61 ± 2 65 ± 6a 61 ± 2
SVR (dyn s cm-5) Group I 2,468 ± 235 (n.d.) 2,647 ± 165c 2,502 ± 131 2,403 ± 127 2,792 ± 224$ 2,765 ± 118c 2,720 ± 113
Group II 2,295 ± 127 1,943 ± 87* 2,039 ± 162c 2,024 ± 98 1,969 ± 84 2,006 ± 78 2,014 ± 178c 2,071 ± 93
VO2 (mL kg
-1 min-1) Group I 3.5 ± 0.1 (n.d.) 3.4 ± 0.1a 3.7 ± 0.1 3.7 ± 0.1 4.1 ± 0.1$ 3.6 ± 0.1a 4.2 ± 0.1
Group II 3.3 ± 0.2 3.7 ± 0.2 3.3 ± 0.3a 3.5 ± 0.1 3.6 ± 0.1 3.8 ± 0.1 3.5 ± 0.2a 3.5 ± 0.2
Values are mean ± SEM for n = 6 per group
Recovery-30 and recovery-60 are measurement points at 30 and 60 min of
normoxic recovery, HR heart rate, MAP mean arterial pressure, SVR sys-
temic vascular resistance, VO2 systemic oxygen consumption
* Significant drug effects of LEVO and $ GLIB
a No difference between hypoxia episodes
b Significant difference within one group’s hypoxia episodes
c Significant difference between the two groups’ hypoxia episodes
706
in a randomized mode on healthy, chronically instru-
mented dogs with intervals of C2 weeks to exclude
carryover effects and to minimize interindividual differ-
ences. Furthermore, the use of chronically instrumented
animals avoided acute, surgical instrumentation and thus
confounders such as endocrine stress responses to sur-
gery. In addition, our model allowed us to study the
animals during sedation with sevoflurane and rocuronium
alone, i.e., without need for analgesics or other con-
founding drugs [42].
Fig. 2 Cardiac output. Cardiac output during normoxia (FiO2
*0.3, thin outlined bars) and the two hypoxia episodes (FiO2
*0.1, bold outlined bars) of the two experimental groups I (left bar
per condition) and II (right bar per condition). Levosimendan was
not given in group I, thus condition LEVO in group I is not
determined (n.d.). Filling patterns: gray no pretreatment, downward
stripes levosimendan (LEVO) pretreatment, upward stripes
glibenclamide (GLIB) pretreatment, hatches levosimendan ? gli-
benclamide pretreatment. Recovery-30 and recovery-60 are
measurement points at 30 and 60 min of normoxic recovery.
Mean ± SEM for n = 6 per group. aNo difference between
hypoxia episodes, bsignificant difference within one group’s
hypoxia episodes, csignificant difference between the two groups’
hypoxia episodes, *significant drug effects of LEVO and $GLIB
Fig. 3 Pressure-curve-derived contractility, ?dP/dtmax. Resulting
?dP/dtmax during normoxia (FiO2 *0.3, thin outlined bars) and
the two hypoxia episodes (FiO2 *0.1, bold outlined bars) of the
two experimental groups I (left bar per condition) and II (right bar
per condition). Levosimendan was not given in group I, thus
condition LEVO in group I is not determined (n.d.). Filling
patterns: gray no pretreatment, downward stripes levosimendan
(LEVO) pretreatment, upward stripes glibenclamide (GLIB)
pretreatment, hatches levosimendan ? glibenclamide pretreatment.
Recovery-30 and recovery-60 are measurement points at 30 and
60 min of normoxic recovery. Mean ± SEM for n = 6 per group.
aNo difference between hypoxia episodes, bsignificant difference
within one group’s hypoxia episodes, csignificant difference
between the two groups’ hypoxia episodes, *significant drug
effects of LEVO and $GLIB
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In this study, two subsequent episodes of hypoxia
were induced per group. While the first hypoxic episode
served to elucidate the effect of LEVO pretreatment, the
second hypoxic episode served to elucidate the role of
KATP
? channels (by subsequently adding GLIB pretreat-
ment, reported to block GLIB-sensitive KATP
? channels
[26–30]). Between the two hypoxic episodes, an exten-
ded normoxic period was interposed to allow complete
recovery of measured variables. In addition, to exclude
the possibility that the first hypoxic episode was
affecting the second with respect to measured variables,
pilot experiments were performed, comparing a first
with a second hypoxic period without adding any
medication (i.e., no GLIB) in between. These pilot
experiments demonstrated no differences between the
first and second hypoxic episode, with respect to the
measured variables.
Gastromucosal lHbO2 was continuously measured by
reflectance spectrophotometry [43], with the light guide
nontraumatically introduced via an orogastric tube [9, 39].
Reflectance spectrophotometry allows determination of
microcirculatory oxygen availability [44], and gastric
endoluminal reflectance spectroscopy has been reported
predominantly to measure capillary hemoglobin oxygen-
ation of the mucosa [45].
Both hypoxia and the administered drugs may affect
pulmonary endothelial permeability. Thus, we assessed
EVLW by the PiCCO system, a method validated in
anaesthetized dogs [37]. The EVLW data do not support
pulmonary edema as cause of the small but significant
differences in PaO2 between distinct hypoxia conditions
(i.e., slightly lower with LEVO and/or GLIB), rendering
an altered pulmonary shunt, as also reported for other
vasoactive agents [46], as the most likely explanation.
LEVO appears to be a promising candidate agent to
support the cardiocirculatory system during hypoxemia,
particularly because circulatory stimulation by LEVO is
reportedly independent of metabolic stimulation [9]. Our
data support this concept, demonstrating that LEVO
pretreatment resulted in improved systemic circulation
(CO) also during hypoxemia without fueling aerobic
(VO2) metabolism. Thus, the pattern of increased CO at
stable VO2 was present also during hypoxemia in LEVO-
pretreated subjects and, in turn, other factors triggered by
hypoxemia, e.g., changed pharmacology [47], did not
alter this pattern. Measured key modulators of vascular
tone (PaCO2, pH, temperature, arterial [K
?] and [Ca2?])
did not differ between the hypoxemic episodes, support-
ing that LEVO-specific mechanisms cause the differences
in cardiovascular response.
The present study was designed to suggest a concept
to improve the condition of the subject before an antici-
pated hypoxemia evolves; however, the majority of
clinical hypoxemia episodes occur unexpectedly. There-
fore, future studies will have to demonstrate if our
findings are confirmed in the clinically more likely
setting, i.e., with LEVO administered in a therapeutic
rather than prophylactic approach [24, 48].
Increased CO during hypoxemia after LEVO pretreat-
ment, compared to unpretreated hypoxemia, was associated
with an increased ?dP/dtmax, compatible with positive
inotropic effects of LEVO by myocardial Ca2? sensitizing.
LEVO, besides acting as a cardiac Ca2? sensitizer,
also activates KATP
? channels. Physiologically, various
KATP
? channel isoforms exist, classified by their respective
sulfonylurea receptors (SUR) in pancreatic b-cells
(SUR-1), and striated (SUR-2A) and smooth muscle cells
(SUR-2B). Vascular smooth muscle KATP
? channels link
regional metabolism to perfusion, since intracellular ATP
depletion (e.g., during hypoxia) triggers these channels,
leading to hyperpolarization and thus vasorelaxation [8].
However, excessive activation of these KATP
? channels is
involved in multiple pathological vasodilatory states, e.g.,
septic shock [8, 25]. Thus, whether pharmacological acti-
vation of KATP
? channels under pathological conditions by
LEVO is beneficial might also depend on the individual
vasodilatory state. Pharmacologically, KATP
? channels are
antagonized by sulfonylurea derivatives, with GLIB (gly-
buride) reported to unspecifically block all receptor
isoforms, SUR-1, SUR-2A, and SUR-2B. GLIB has been
reported to be effective as a KATP
? channel antagonist in dogs
before, in similar dosages as applied in the present study
[26–30]. Activity of GLIB in our model is suggested by the
hypoglycemic response after GLIB pretreatment (SUR-1
effect), with arterial glucose decreased from baseline values
of *100 to *50 mg dL-1 (end of experiments). In addi-
tion, GLIB pretreatment significantly increased SVR,
suggesting (partial) blockade of vascular KATP
? channels.
Thus, although GLIB pretreatment significantly
increased SVR in this model, the demonstrated marked
hypoglycemic effect of GLIB may limit its clinical use.
Combined GLIB ? LEVO pretreatment resulted in
significantly higher CO and ?dP/dtmax than GLIB pre-
treatment alone during hypoxemia, compatible with the
notion that mechanisms other than KATP
? channel opening
contribute to LEVO effects, also during hypoxemia.
Besides Ca2? (re-)sensitization, LEVO’s action as a
phosphodiesterase (PDE) inhibitor could also contribute.
In this regard, other PDE-III inhibitors have demonstrated
positive systemic and regional gastrointestinal mucosal
effects during hypoxemia [14].
Despite significant systemic differences, regional
gastromucosal oxygenation did not differ between LEVO-
pretreated and unpretreated hypoxemia, which decreased
equally to *30%. Regional regulation of mucosal per-
fusion during hypoxemia could overrule the effects of
LEVO, despite an increased CO and reduced SVR in
LEVO-pretreated hypoxia. A possible mechanism is that
local hypoxia activates vasodilatory KATP
? channels to
such extents that LEVO can not confer significant addi-
tional vasodilation. Indeed after GLIB pretreatment,
administered to block these vasodilatory KATP
? channels
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and thus to induce vasoconstriction, we observed clear
trends towards lower lHbO2 both in LEVO-pretreated
(from 32 ± 4 to 24 ± 4%) and unpretreated hypoxemia
(from 30 ± 4 to 25 ± 3%). Interestingly, also in both
groups arterial lactate concentrations were significantly
lower after GLIB pretreatment. Since arterial pH and the
other acid/base-related variables remained close to base-
line under all hypoxemia conditions, we doubt that these
significant differences in lactate concentration are caused
by different perfusion states, rendering direct metabolic
effects of GLIB more likely to contribute.
LEVO is clinically indicated for the treatment of
chronic or acute cardiac failure, with promising results [15,
16], and indications have already extended to septic and
toxic cardiac depression [17–23]. If our experimental data
apply to the clinical setting, LEVO pretreatment may also
be an option to support the cardiovascular system during
hypoxemia, without fueling VO2, without aggravating
systemic anaerobiosis markers, and without further com-
promising the regional gastromucosal oxygenation. Further
studies will have to extend these experimental results to
other hypoxia models and ultimately to the clinical setting.
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